| Popis: |
We examined 76 women aged 59-69 years in the postmenopausal period with manifestations of menopausal syndrome. All women underwent a general clinical examination, including anamnesis collection and physical examination with weight measurement, gynecological examination, smear taking for oncocytology and blood pressure monitoring. In the group of women we examined, there were no indications for the appointment of an additional examination. Mammography, ultrasound of the pelvic organs, biochemical blood analysis (with determination of total protein, glucose, creatinine, bilirubin, AlT, AsT, alkaline phosphatase, calcium, phosphate content), coagulogram were performed, and serum concentrations of FSH, LH and estradiol were studied. The blood lipid spectrum and its parameters were studied: total cholesterol, triglycerins, β-lipoproteins). An ECG was performed. Bone mineral density was determined by two-energy X-ray densitometry. All these studies were performed primarily during therapy at 6 and 9 months and 1 year after therapy with tibolone. Various manifestations of postmenopausal menopausal menopausal syndrome were detected in all the examined patients and had different degrees of severity: endocrine-metabolic, urogenital, manifestations of osteoporosis were most pronounced in women who had passed more than ten years since menopause. The appointment of therapy with tibolone normalized the atherogenic potential of the blood, had a beneficial effect on the cardiovascular system, and stopped the manifestations of osteoporosis. There was a good tolerability of the drug, no side effects were registered. Keywords. Menopausal syndrome, osteoporosis, menopausal hormone therapy, tibolone. |
